Summary
Introduction
Somaxon Pharmaceuticals (Somaxon) is a development stage pharmaceutical company engaged in in-licensing and developing proprietary product candidates for the treatment of psychiatry and neurology disorders. In January 2008, Somaxon submitted NDA with the FDA for Silenor for the treatment of insomnia.
Scope
Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
Somaxon Pharmaceuticals enters into licensing agreements with pharmaceutical companies for developing therapeutics. In 2003, the company entered into licensing agreement with ProCom One for the exclusive, worldwide license to certain patents to develop and commercialize low dosages of Silenor for the treatment of insomnia. In the following year, BioTie Therapies granted the license of oral nalmefene hydrochloride to Somaxon. In addition, Somaxon received exclusive worldwide rights from Synchroneuron to certain patents to develop, manufacture and market acamprosate. During the forecast period 2006-2010, Somaxon is expected to derive its entire revenues from the launch of Silenor in 2009. Product sales of Silenor are expected to grow from $71 million in 2009 to $119 million in 2010.
Reasons to Purchase
Access all the important information and analysis on the company in a single report Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company's adjusted five year financial data along with key ratios and market capitalization.
|
